Pretreatment tumoural perfusion correlates with an imaging-based response to dexamethasone in patients with glioblastoma multiforme

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 81, Issue 4, 2010, Pages 446-448

  Armitage, Paul A ^a   Schwindack, Chris ^a   Bastin, Mark E ^a   Whittle, Ian R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DEXAMETHASONE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; ARTICLE; BRAIN BLOOD VOLUME; BRAIN PERFUSION; CANCER GRADING; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; FEMALE; GLIOBLASTOMA; HUMAN; LIQUORRHEA; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BLOOD FLOW;

EID: 77950597032     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.161240     Document Type: Article

References (15)

1. Galicich JH, French LA, Melby JC. Use of dexamethasone in the treatment of cerebral edema associated with brain tumours. Lancet 1961;81:46-53.
2. Vecht CJ, Hovestadt A, Verbiest HB, et al. Doseeeffect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4,8, and 16 mg per day. Neurology 1994;44:675-80.
3. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative diffusion tensor MRI. J Magn Reson B 1996;111:209-19.
4. Ostergaard L, Weisskoff RM, Chesler DA, et al. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages: Part 1. Mathematical approach and statistical analysis. Magn Reson Med 1996;36:715-25.
5. Tofts PS, Kermode AG. Measurement of the bloodebrain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991;17:357-67.
6. Beauregard DA, Parker D, Brindle KM. Relaxation-based mapping of tumour pH. In: Proceedings of the 6th Annual Meeting of ISMRM; Sydney, Australia: 1998. p.53.
7. Andersen C, Haselgrove JC, Doenstrup S, et al. Resorption of peritumoral edema in cerebral gliomas during dexamethasone treatment evaluated by NMR relaxation time imaging. Acta Neurochir 1993;122:218-24.
8. Andersen C, Jensen FT. Differences in bloodetumour-barrier leakage of human intracranial tumours: quantitative monitoring of vasogenic oedema and its response to glucocorticoid treatment. Acta Neurochir 1998;140:919-24.
9. Ostergaard L, Hochberg FH, Rabinov JD, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and bloodebrain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 1999;90:300-5.
10. Sinha S, Bastin ME, Wardlaw JM, et al. Effects of dexamethasone of peritumoural oedematous brain: a DT-MRI study. J Neurol Neurosurg Psychiatry 2004;75:1632-5.
11. Armitage PA, Schwindack C, Bastin ME, et al. Quantitative assessment of intracranial tumor response to dexamethasone using diffusion, perfusion and permeability magnetic resonance imaging. Magn Reson Imaging 2007;25:303-10.
12. Bastin ME, Carpenter TK, Armitage PA, et al. Effects of dexamethasone on cerebral perfusion in patients with high-grade glioma. Am J Neuroradiol 2006;27:402-8.
13. Armitage P, Behrenbruch C, Brady M, et al. Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast. Med Image Anal 2005;9:315-29.
14. Henderson E, Rutt BK, Lee TY. Temporal sampling requirements for the tracer kinetics modeling of breast disease. Magn Reson Imaging 1998;16:1057-73.
15. Zbinden L, Pandey R, Schwindack C, et al. Information processing in patients with intracranial tumours: a preliminary evaluation of the clinical utility of inspection time. Br J Neurosurg 2006;20:203-8.